Type 2 diabetes is a complicated disease influenced by genetics, lifestyle, and environment. Now, an international consortium of scientists has uncovered some previously unknown genetic factors — which could potentially aid the search for better treatments.
The researchers sequenced the exomes — all the protein-coding genes — of roughly 21,000 people with type 2 diabetes and 25,000 healthy controls. They found rare variants in four genes (SLC30A8, MC4R, PAM, and UBE2NL) that influence diabetes risk. These included 30 protective variants in the SLC30A8 gene.
“We now have an updated picture of the role of rare DNA variations in diabetes,” says Jason Flannick, PhD, a computational scientist specializing in genetics and the study’s first author. “They potentially provide a much more valuable resource for drug development than previously thought.”
These variants and genes could also help reveal more about the biology of type 2 diabetes, says Flannick, whose lab is based at Harvard Medical School, the Broad Institute, and the Division of Genetics and Genomics at Boston Children’s Hospital. The study was published last week in Nature.
Globalizing the search for genes
Apart from its massive size, a major strength of the study is its diverse cohort. Subjects included people of European, African American, Hispanic/Latino, East Asian, and South Asian background.
“These results demonstrate the importance of studying large samples of individuals from a wide range of ancestries,” said Michael Boehnke, PhD, the study’s senior author and director of the Center for Statistical Genetics at the University of Michigan School of Public Health. “Most large population studies focus on individuals of European ancestry, and that can make it hard to generalize the results globally. The more diverse the cohort makes for better, more informative science.”
Involving nearly 50,000 people, this may be the largest exome sequencing study of type 2 diabetes to date. But the researchers believe that with larger sample sizes, they could find additional rare variants, perhaps hundreds more. This could require sample sizes of 75,000 and 185,000 cases.
In the meantime, the team has made its results available for use by scientists around the world through the Type 2 Diabetes Knowledge Portal.
Other senior authors on the paper include Mark McCarthy, MD, of the University of Oxford, and Jose Florez, MD, PhD, of Massachusetts General Hospital, Harvard Medical School, and the Broad Institute. Funders include the NIH, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Human Genome Research Institute, and the Carlos Slim Foundation.
Related Posts :
Made-to-order therapies get a boost with new FDA guidelines
Science-based treatments for rare genetic diseases have burgeoned in the past decade. That includes diseases so rare they affect just ...
Hip reconstruction in complex patients: Predicting complications
Neuromuscular hip dysplasia and progressive spastic hip displacement are among the most common orthopedic concerns in non-ambulatory children with cerebral ...
Matthew, the ‘wee marvel’: The first gene therapy ALD recipient
When the Elliott brothers are asked how many siblings they have, they always say, “four.” It’s a way of ...
COVID-19 vaccines: Do you know myth from fact?
Two COVID-19 vaccines — from Pfizer/BioNTtech and Moderna — have received emergency use authorization in the United States by the ...